Partner With Us
Increase Visibility of Your Capabilities to the Industry’s Leading Minds in Dermatology
Investment towards inflammatory disease is fast-gaining traction, evidenced by Johnson & Johnson’s $2.1bn play for bispecific biotechs. Triggering increasing competition pressure, biopharma are actively looking for efficient, reliable, and innovative solutions and services to expedite their inflammatory skin disease-targeted pipeline.
Faced with Challenges to Address, Biopharma Told Us Their Priorities in 2024 Were:
- Addressing disease model variability
- Developing validated biomarker assays and diagnostics
- Defining robust endpoints
- Enhancing patient recruitment and retention
- Improving data management
- Managing complex formulation manufacture
These challenges demanded solutions that offer both speed and sophistication.
The 8th Dermatology Drug Development Summit had a proven reputation for initiating meaningful and long-lasting collaborations between leading pharma and industry event partners, and stood as the largest industry-led forum for dermatology leaders specific to the immune-inflammatory skin condition space.
130+ gathered, including decision makers from pharma’s Discovery, Translational, Clinical, and Business Development teams, and our partners capitalized on a unique opportunity to position their brand at the forefront of dermatological innovation.
Who Attended?
